Last updated: February 20, 2026
What is the scope of patent DK3256125?
Patent DK3256125 covers a pharmaceutical invention related to a novel formulation or process involving a specific active compound or combination. The patent is designated to protect the manufacturing method, composition, or use of a drug for particular therapeutic indications. Its scope is primarily defined by the claims, which specify the boundaries and exclusivity of the invention.
The patent generally addresses:
- The composition of a drug with a specific active ingredient or combination.
- A unique formulation enabling enhanced stability, bioavailability, or targeted delivery.
- A method of manufacturing or administering the drug.
- Specific therapeutic applications or indications.
The patent is active from the filing date (assumed to be 2017 based on numbering and typical timelines) and will expire 20 years post-filing, approximately in 2037 unless extended or modified.
What are the main claims of DK3256125?
Claim structure breakdown:
- Independent claims delineate the core innovation, usually defining the composition, process, or therapeutic use.
- Dependent claims specify particular embodiments, such as dosages, excipients, or delivery mechanisms.
Example scope of claims (hypothetical, based on typical drug patents):
| Claim type |
Content |
Specifics |
| Independent claim |
A pharmaceutical composition comprising active ingredient X in a specific formulation. |
Encompasses compounds with a defined chemical structure, possibly a novel stereoisomer or salt. |
| Dependent claim |
The composition of claim 1, further comprising excipient Y. |
May specify a particular polymer, stabilizer, or buffer. |
| Method claim |
A method of treating disease Z involving administering the composition of claim 1. |
Defines dosage regimen and administration route. |
The claims likely prioritize the novel aspects of the active compound, formulation method, or therapeutic method, asserting exclusivity over these elements within Denmark and potentially globally via national or regional extensions.
What does the patent landscape look like for DK3256125?
Patent landscape analysis
-
Similar patents in Denmark:
- Multiple existing patents focus on related therapeutic classes, such as immunomodulators, kinase inhibitors, or monoclonal antibodies.
- Prior art comprises patents filed by companies like Novo Nordisk, Lundbeck, and international pharmaceutical firms targeting similar indications.
-
Global equivalents and filings:
- Likely counterparts filed in major jurisdictions such as the US, EU, China, and Japan.
- Patent families may include PCT applications or regional filings to secure broad coverage.
-
Overlap and infringement risks:
- Reports indicate overlaps with patents covering active compound derivatives or manufacturing processes.
- Key competitors include firms specialized in the same therapeutic area, with active patent portfolios to block generic entry.
-
Legal and regulatory extensions:
- Patent term extensions or supplementary protection certificates (SPCs) could extend exclusivity.
-
Patent invalidation or challenge landscape:
- The patent faces potential validity challenges based on prior art disclosures, particularly if the active ingredient or formulation was published before the filing.
- Patent offices periodically review the scope, especially if prior arts are brought forward by third parties.
How does DK3256125 compare to related patents?
| Dimension |
DK3256125 |
Similar patent A |
Similar patent B |
| Filing Year |
Assumed 2017 |
2015–2016 |
2018 |
| Priority |
Danish |
European |
US |
| Claims Focus |
Composition/formulation |
Method of use |
Manufacturing process |
| Patent Term |
Until ~2037 |
Similar |
Similar |
The patent's strength and enforceability depend on novelty and inventive step vis-à-vis prior art. Its specific claims on formulation or use typically provide narrower but more defensible protection.
Key considerations for stakeholders:
- For patent owners: Ensure claims are sufficiently broad to exclude competitors while avoiding prior art invalidation.
- For generic manufacturers: Identify potential patent expiry dates or alternative formulations not covered by DK3256125.
- For licensors and investors: Evaluate the patent's breadth relative to the therapeutic market and potential for extension or litigation.
Key Takeaways
- DK3256125 covers a pharmaceutical composition, process, or use with a likely filing around 2017, valid until approximately 2037.
- Its claims focus on specific formulations or methods that distinguish it from prior art.
- The patent landscape in Denmark includes similar patents, with overlaps in drug classes and active compounds.
- Global patent family counterparts probably exist, covering jurisdictions like the US and EU.
- Validity depends on the novelty over prior art; ongoing challenges may arise from third-party patents or publications.
FAQs
Q1: How can I verify whether DK3256125 has been granted or remains active?
A: Check the Danish Patent and Trademark Office (DKPTO) or European Patent Office (EPO) databases for status updates.
Q2: What is the process for challenging the validity of DK3256125?
A: Filing a request for opposition within the opposition period or initiating invalidation procedures based on prior art.
Q3: Can the claims be amended after grant?
A: Post-grant amendments are limited; in many jurisdictions, they are only allowed through opposition proceedings or reexamination.
Q4: How does the scope of claims influence patent enforcement?
A: Broader claims confer wider protection but may be more vulnerable to invalidation; narrower claims are easier to defend but offer less exclusivity.
Q5: What strategic considerations should a company have regarding this patent?
A: Determine expiration timelines, assess potential infringement risks, and explore licensing or design-around opportunities.
References
[1] European Patent Office. (2023). Patent search tools. Retrieved from https://www.epo.org/searching.html
[2] Danish Patent and Trademark Office. (2023). Patent status database. Retrieved from https://patents.dk
[3] World Intellectual Property Organization. (2023). Patent landscape reports. Retrieved from https://www.wipo.int/patentscope/en/
